TLM Utility Nav

Behind the Scenes of Steatotic Liver Disease: From Research Idea to High-Impact Publication

Description

In this clinical research "fireside chat," authors of manuscripts published in high-impact journals that address the spectrum of steatotic liver disease with diverse research methodologies discuss their work—from study conception to implications of study findings. The session provides an in-depth exploration of the research process from the perspective of the investigator and their team. Presenters briefly discuss how they took an initial idea to study design to execution and publication. Presentations are followed by a more informal and interactive discussion between the presenters and moderators within the framework of a critical review, with a focus on challenges encountered during the process and creative strategies to overcome them. This program provides an opportunity for clinical attendees to explore the findings of recent, high-impact steatotic liver disease publications.

Journey Maps

Presentations

11:00 AM - 11:15 AM
Nov 18 2024
San Diego, CA

"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH"

Rohit Loomba, MD, MHSc, FAASLD, Presenter
ALD
MASLD
11:15 AM - 11:30 AM
Nov 18 2024
San Diego, CA

"Validation of the New Nomenclature of Steatotic Liver Disease in Patients With a History of Excessive Alcohol Intake: An Analysis of Data From a Prospective Cohort Study"

Maja S. Thiele, MD, Presenter
ALD
MASLD
11:30 AM - 11:45 AM
Nov 18 2024
San Diego, CA

"The Steatosis-Associated Fibrosis Estimator (SAFE) Score: A Tool to Detect Low-Risk Non-Alcoholic Fatty Liver Disease in Primary Care"

W. Ray Kim, MD, FAASLD, Presenter
ALD
MASLD
11:45 AM - 12:00 PM
Nov 18 2024
San Diego, CA

Retail Alcohol and Tobacco Sales During COVID-19

Brian P Lee, MD, Presenter
ALD
MASLD
12:00 PM - 12:15 PM
Nov 18 2024
San Diego, CA

Full Panel Questions and Answers

Elliot Tapper, MD, FAASLD, Presenter
ALD
MASLD
12:15 PM - 12:30 PM
Nov 18 2024
San Diego, CA

"Longitudinal Changes in Fibrosis Markers Are Associated With Risk of Cirrhosis and Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease"

George Cholankeril, MD, Presenter
ALD
MASLD

Objectives

  • Discuss the research process including opportunities and challenges in conducting clinical research.
  • Critically review recent high-impact publications addressing steatotic liver disease.
Chair

Allison Kwong, MD

Stanford University Medical Center
Chair

Kali Zhou, MD, MAS